Skip to main content
. 2018 Sep 14;24(34):3871–3883. doi: 10.3748/wjg.v24.i34.3871

Figure 1.

Figure 1

Middle dosage of FK506 is optimal for maintaining immunosuppression after liver transplantation. A: Representative image of the hepatic graft pathological structure stained with hematoxylin and eosin (HE, 200 ×); B: Representative hepatocyte ultrastructure obtained via transmission electron microscopy (TEM, 2550 ×, 12500 ×); C: Assessment of hepatic graft function by plasma levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in different treatment groups. N: Cell nucleus; M: Mitochondria. aP < 0.05; bP < 0.01; cP < 0.001.